Illumina releases in vitro cancer profiling test

2020 01 14 22 12 7635 Dna Sequencing2 400

Illumina has launched TruSight Oncology Comprehensive, a test that examines tumor genes and biomarkers to define the specific molecular profile of a patient's cancer.

The company is releasing the test first in Europe, it said. TruSight Oncology Comprehensive assesses biomarkers in 517 cancer-relevant genes across 30 solid-tumor cancer types through analysis of DNA, RNA, and genomic signatures. It is the first CE-marked in vitro diagnostic genomic profiling kit based on DNA and RNA content, according to the firm.

Page 1 of 92
Next Page